Imagion Biosystems Limited

ASX:IBXDA Stock Report

Market Cap: AU$10.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Imagion Biosystems Past Earnings Performance

Past criteria checks 0/6

Imagion Biosystems's earnings have been declining at an average annual rate of -12.6%, while the Medical Equipment industry saw earnings growing at 5.8% annually. Revenues have been growing at an average rate of 16.5% per year.

Key information

-12.6%

Earnings growth rate

34.9%

EPS growth rate

Medical Equipment Industry Growth5.8%
Revenue growth rate16.5%
Return on equityn/a
Net Margin-335.6%
Last Earnings Update30 Jun 2023

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Imagion Biosystems makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:IBXDA Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 233-1290
31 Mar 233-1190
31 Dec 223-1080
30 Sep 222-1070
30 Jun 220-1060
31 Mar 222-860
31 Dec 213-660
30 Sep 213-660
30 Jun 213-560
31 Mar 213-550
31 Dec 203-550
30 Sep 203-540
30 Jun 202-440
31 Mar 202-440
31 Dec 192-330
30 Sep 192-440
30 Jun 192-550
31 Mar 191-750
31 Dec 180-860
30 Sep 180-861
30 Jun 180-861
31 Mar 180-852
31 Dec 170-852
31 Dec 160-1216
31 Dec 150-404
31 Dec 140-302

Quality Earnings: IBXDA is currently unprofitable.

Growing Profit Margin: IBXDA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IBXDA is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.

Accelerating Growth: Unable to compare IBXDA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IBXDA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-3%).


Return on Equity

High ROE: IBXDA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies